Today’s $60m deal is focused on Lp(a), a new cardiovascular target for the gene editing company.
Lilly is the latest group, after Biogen and Sanofi, to collaborate on Scribe’s novel approach to Crispr editing.
Alzheimer’s has already grabbed attention but plenty of big regulatory decisions still loom for Sarepta, Crispr, Astellas and more.
A new report from Evaluate Vantage looks at recent developments in gene editing and delivery.
The developer has two new collaborations in rare dystrophies, with Entrada and Tevard, but work is early and certain rivals are some way ahead.